리팜피신과 오플록사신에 내성인 Bacillus coagulans OFR17 균주

• 영문명: Bacillus coagulans OFR17 Strain Resistant to Rifampicin and Ofloxacin
• 발행기관: 대한약학회
• 저자명: 김은아(Eun Ah Kim) 오태권(Tae Kwon Oh) 최금화(Keum Hwa Choi) 이진희(Jin Hee Lee) 백문창(Moon Chang Baek) 김병각(Byong Kak Kim) 최응칠(Eung Chil Choi)
• 간행물 정보: 『약학회지』제41권 제4호 (1997년), 450~455쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 1997.08.30

영문 초록

The preparation of Bacillus coagulans is used as a therapeutics for human intestinal disorders. However, the bacterium in the preparation is very susceptible to rifampicin and fluoroquinolones. When the preparation is taken with rifampicin or fluoroquinolones, its therapeutic effect can not be expected. So B. coagulans RFR17 resistant to rifampicin was obtained by treating the parent B. coagulans with N-methyl-N'-nitro-N-nitrosoguanidine. B. coagulans OFR17 was produced by serial passage of B. coagulans RFR17 on agar with 2-fold minimal inhibitory concentration of ofloxacin or ciprofloxacin. B. coagulans OFR17 was resistant to fluoroquinolones up to 16~64 fold higher than that for the original strain. B. coagulans OFR17 also exhibited identical characteristics with the parent strain when they were tested for lactic acid production and growth inhibition of E. coli MB4-01 and Shigella sonnei MB4-10411. From in vitro test, it was also identified that rifampicin and ofloxacin are not inactivated by certain factors of B. coagulans OFR17. Conclusively, B. coagulans OFR17 can be regarded as a promising strain which can be developed as the preparation for the treatment of the intestinal disorders of the tuberculosis patients under rifampicin and ofloxacin therapy.

키워드

Bacillus coagulans 0FR17 rifampicin fluoroquinolones multi-step mutation resistance.